Inmune Bio, Inc.
Clinical trials sponsored by Inmune Bio, Inc., explained in plain language.
-
Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early
Disease control TerminatedThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whet…
Phase: PHASE2, PHASE3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control TerminatedThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC